Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.
We report on 2 patients with idiopathic Parkinson's disease who experienced marked improvement in symptoms following the addition of itraconazole to current cabergoline treatment. Plasma levels of cabergoline were analyzed in one of the patients and increased to approximately 300% during treatment with itraconazole, which paralleled major clinical improvement.
Christensen
Jakob
J
Centre for Clinical Pharmacology, University of Aarhus, Aarhus, Denmark. Jakob@farm.au.dk
Dupont
Erik
E
ØStergaard
Karen
K
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage*; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000077465:Cabergoline; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage*; D008297:Male; D009460:Neurologic Examination / Q000187:drug effects; D014009:Onychomycosis / Q000097:blood / Q000188:drug therapy; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
D000935:Antifungal Agents; D000978:Antiparkinson Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D004873:Ergolines; D017964:Itraconazole; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D000077465:Cabergoline